Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

Lilly is testing bimagrumab alone and in combination with Novo's Wegovy -- a mid-stage trial begun before the acquisition -- ...

A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.